IXICO are awarded two further contracts in HD
IXICO continue their work in Huntington's Disease after being awarded two further contracts for separate clinical trials with top 15 pharma companies.
Huntington's Disease (HD) is a rare genetic neurodegenerative disorder for which there are currently no effective marketed treatments. Despite it's low incidence (5-7 people per 100,000), there is a significant interest from pharmaceutical and biotech companies to invest in therapeutics to treat the disease.
IXICO has been involved in supporting research in HD for many years, having worked with key opinion leaders and charitable organisations in this field since 2007. These two new clinical trials, involving imaging centres across North America and Europe, are due to begin imminently and are expected to last a minimum of two years. They will call upon IXICO's expertise in functional MRI, structural MRI, magnetic resonance spectroscopy (MRS), and diffusion tensor imaging (DTI).
To view the complete press release and for a statement from Professor Derek Hill, CEO IXICO plc, please see the attached file.